IRR
Upto 22.4%
A Strategy Built on Precision, Protection, and Proven Performance
Our investment approach is engineered like a physician's decision-making process: evidence-based, risk-aware, and guided by disciplined protocols. Every allocation aligns with the goal of delivering stable, durable, and compounding wealth.
4
INVESTMENT PILLARS
12.6%
APPROVAL RATE
0
CAPITAL CALLS
Transactional Value
$750M+
STRATEGY OVERVIEW
Disciplined. Data-First.
Medtech & Biotech
22.4% IRR
Pre-IPO Technology
3.2× Multiple
Build-to-Rent Real Estate
18–24% IRR
Private Credit
12–18% Yield
$750M+
TRANSACTIONAL VALUE
5+ Years
OUTPERFORMANCE
OUR PHILOSOPHY
The Three Pillars of the Baluch Capital Strategy
A simple, robust framework applied across all investments.
Preserve Capital First
-
Downside protection as top priority
-
Collateral, senior liens, conservative underwriting
-
Zero capital calls
-
Risk checked before return potential
Seek High-Conviction Alternatives
-
Focus on sectors with asymmetric potential
-
Non-correlated sources of return
-
Access-tier opportunities normally reserved for institutions
Structure for Physician Reality
-
Passive, predictable, low-monitoring investments
-
Quarterly distributions on majority of deals
-
Clear timelines, no trading, no constant decision fatigue
— OUR FOUR PILLARS
A Diversified Strategy Grounded in Opportunity and Protection
Each sector is selected for its risk-adjusted return profile, resilience, and long-term value creation.
Medtech & Biotech
BioWise Fund
Why we invest here:
Advancements in diagnostics, digital medicine, surgical robotics, molecular technologies.
Key Metrics:
Portfolio companies
Successful exits
Companies entering FDA trials
Historical IRR
Loss ratio
16
Pending
2
22.4%
0%
Investment Edge:
Physician-founded insight → superior evaluation of clinical potential + scientific validity.
Pre-IPO Technology
Eagle Fund
Why we invest here:
High-growth tech firms at late-stage valuations (AI, cybersecurity, enterprise SaaS, data infra).
Key Metrics:
Avg entry discount
Target multiple
Access type
Sector exit multiple
41–63% below IPO
3×+
Private networks
3.2×
Investment Edge:
Deals unavailable to the public or traditional advisors.
Build-to-Rent Real Estate
Residential Real Estate
Why we invest here:
Housing demand, migration trends, resilient cash flow, institutional exit demand.
Key Metrics:
Markets
Avg occupancy
Rent growth YoY
IRR range
Dallas, Austin, Phoenix
94%
6–9%
18–24%
Investment Edge:
Partnerships with proven builders + conservative underwriting + low leverage.
Private Credit / Specialty Lending
Collateralized Lending
Why we invest here:
Short-duration loans backed by real assets, predictable yield, secured downside.
Key Metrics:
Avg yield
LTV
Collateral-backed
Default rate
12–18%
<50%
100%
0%
Investment Edge:
Strong legal protection + cash-flow priority.
RETURN CONTRIBUTION
Where Our Returns Come From
A balanced mix of high-growth appreciation, stable yield, and equity value creation — carefully weighted to reduce volatility and improve downside resilience.
.png)
Pre-IPO Tech
Real Estate
Private Credit
Medtech/Biotech
Structured Deals
31%
27%
22%
14%
6%
TOTAL PILLARS
5
LARGEST ALLOCATION
31%
DIVERSIFICATION
Balanced
— RISK FRAMEWORK
Institutional-Grade Risk Controls, Modeled After Clinical Decision Systems
Capital is protected through structured analysis, layered security, and objective decision protocols.
Senior lien protection
Priority position in capital structure
<47% average loan-to-value
Conservative leverage ratios
Multi-stage due diligence
Comprehensive evaluation protocols
Third-party verification
Independent audit and validation
Worst-case scenario modeling
Stress testing under adverse conditions
Conservative exposure caps
Diversification and position sizing
OUR PHILOSOPHY
Our investment process begins with risk containment, not return projection, mirroring the discipline of clinical practice.
— OUR PROCESS
From 142 Deals to the Top 12.6%
A structured, disciplined investment committee evaluating opportunities through quantitative + qualitative filters.
01
Deal Sourcing
Opportunities from physician networks, institutional partners, PE groups
02
Screening & Fit Assessment
Based on sector, risk, timing, and physician alignment.
03
Deep-Dive Analysis
120+ hours of modeling, underwriting, valuation, and risk assessment.
04
Third-Party Verification
External legal, financial, and technical audits.
05
Investment Committee Approval
Only 12.6% of opportunities proceed.
Our Selection Rate
12.6%
of deals approved
Total Deals Evaluated
142
opportunities
WHY THIS MATTERS
A Strategy Built for the Unique Realities of Physicians
Designed for busy professionals who value their time, clarity, and long-term financial security
Time Efficiency
Zero active management required. Passive, predictable, high-clarity allocations.
Cognitive Simplicity
No trading, complexity, or platform overload. Reporting built for clarity.
Income Stability
Predictable distributions across majority of structures.
Low Correlation
Reduced exposure to public markets that fluctuate with global news cycles.
OUTCOMES
What This Strategy Has Delivered
A disciplined, data-driven approach that has consistently delivered results for physicians seeking stable, long-term wealth creation.
.png){kind=small}
$750M+
transactional value
0
capital calls
.png){kind=small}
16+
medtech investments
5+ years
outperformance vs public markets
Ready to Apply This Strategy to Your Wealth?
Join physicians who have already benefited from our disciplined, evidence-based investment approach. Schedule a confidential consultation to explore how our four-pillar strategy aligns with your financial goals.
Confidential Consultation
No Obligation Discussion
30-Minute Call